Loading…
Sunshine Biopharma, Inc. is projected to rise to $1.58 by 2027, a +35% move from its current price of $1.17. SBFM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.12 | $1.17 | $1.23 | +0.15% |
| Aug 6 | $1.09 | $1.17 | $1.26 | +0.30% |
| Aug 7 | $1.08 | $1.18 | $1.28 | +0.45% |
| Aug 8 | $1.07 | $1.18 | $1.30 | +0.61% |
| Aug 9 | $1.06 | $1.18 | $1.32 | +0.76% |
| Aug 10 | $1.05 | $1.18 | $1.33 | +0.91% |
| Aug 11 | $1.04 | $1.18 | $1.35 | +1.06% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.04 | $1.18 | $1.35 | +1.06% |
| Week 2 | $0.9924 | $1.19 | $1.44 | +2.14% |
| Week 3 | $0.962 | $1.21 | $1.52 | +3.22% |
| Week 4 | $0.9386 | $1.22 | $1.59 | +4.32% |
| Week 5 | $0.9196 | $1.23 | $1.65 | +5.43% |
| Week 6 | $0.9037 | $1.25 | $1.72 | +6.55% |
| Week 7 | $0.8901 | $1.26 | $1.78 | +7.68% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Sunshine Biopharma, Inc. operates as a pharmaceutical company that engages in the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; and K1.1 mRNA, a lipid nano-particle for liver cancer.
It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. Sunshine Biopharma, Inc. is based in Fort Lauderdale, Florida.
The asset is Sunshine Biopharma, Inc. (SBFM), a healthcare stock. It currently trades at $1.23 and carries a market capitalization of $1.99M, with a rank of 5442. The price snapshot shows a neutral technical stance with RSI 14 at 20, and trend markers SMA50 at $2.44 and SMA200 at $10.27.
There is support at $1.23 and resistance at $2.18, while the 30-day price range spans $0.8732 to $1.73 and annualized volatility sits at 100%. Forecast outlook indicates near-term stability through 2026 (min $1.23, avg $1.23, max $2.00; ROI 0) and a bullish trajectory from 2027 onward, with 2030 averaging $1.79 and 2050 averaging $5.19, alongside a max of $11.93 and an overall ROI of 321.7% by 2050.
A major floor 75.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 86.3% above — a clean break opens room to run.
A major ceiling 127.4% above — clearing it would confirm fresh momentum.
Key SBFM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SBFM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.32 | Sell | $1.32 | Sell |
| MA 10 | $1.52 | Sell | $1.48 | Sell |
| MA 20 | $1.76 | Sell | $1.66 | Sell |
| MA 50 | $1.84 | Sell | $1.69 | Sell |
| MA 100 | $1.41 | Sell | $1.57 | Sell |
| MA 200 | $1.41 | Sell | $3.46 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 23.88 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -163.55 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.08 | Sell |
| ROC (12) | -37.10 | Sell |
| Bollinger %B (20,2) | 0.01 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.71 | Sell |
| Awesome (5,34) | -0.60 | Sell |
| Ultimate (7,14,28) | 5.96 | Buy |
| Momentum (10) | -0.63 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 1.12 | Buy |
| ADX (14) | 26.18 | Sell |
| ATR (14) | 0.08 | Info |
The 30-day price range is $0.8732 to $1.73, placing the current price of $1.23 near the lower end of the range and near established support. RSI14 is 20, suggesting a potential oversold condition in the near term, while overall sentiment remains NEUTRAL. SMA50 sits at $2.44 and SMA200 at $10.27, both above the current price, indicating potential resistance to a near-term rally.
Support is identified at $1.23 and resistance at $2.18, framing a cautious near-term picture with limited upside until the price can clear the $2.18 resistance.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.17 | $1.17 | $1.84 | 0% | Neutral | |
| $1.17 | $1.58 | $2.31 | +35% | Bullish | |
| $1.32 | $1.90 | $2.95 | +62% | Bullish | |
| $1.26 | $1.90 | $3.09 | +62% | Bullish | |
| $1.09 | $1.70 | $2.88 | +46% | Bullish | |
| $0.9578 | $1.56 | $2.73 | +34% | Bullish | |
| $0.8874 | $1.50 | $2.71 | +29% | Bullish | |
| $1.05 | $1.84 | $3.41 | +58% | Bullish | |
| $1.18 | $2.16 | $4.09 | +84% | Bullish | |
| $1.21 | $2.28 | $4.41 | +95% | Bullish | |
| $1.04 | $2.31 | $4.89 | +97% | Bullish | |
| $2.17 | $4.81 | $11.07 | +311% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.17 | $1.17 | $1.54 | +0.00% |
| September 2026 | $1.13 | $1.37 | $1.73 | +17.07% |
| October 2026 | $1.09 | $1.34 | $1.73 | -1.97% |
| November 2026 | $1.06 | $1.31 | $1.71 | -2.47% |
| December 2026 | $1.12 | $1.40 | $1.84 | +6.55% |
Click any year to see its month-by-month SBFM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Sunshine Biopharma, Inc.'s 2026 outlook centres on $1.17, within a $1.17 to $1.84 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, SBFM could reach as high as $2.31, with a base case around $1.58 and support toward $1.17 — roughly +35% from $1.17. Momentum favours further upside here.
Expect SBFM to range from $1.32 to $2.95 through 2028. The $1.90 average target implies a +62% move from current prices. That is up +20% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The SBFM price prediction for 2029 points to an average of $1.90 (low $1.26, high $3.09) — a potential gain of +62% on today's $1.17. Momentum favours further upside here.
In 2030, SBFM is projected to trade between $1.09 and $2.88, averaging $1.70 — a potential gain of +46% from today's $1.17. That is -10% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
Sunshine Biopharma, Inc.'s 2031 outlook centres on $1.56, within a $0.9578 to $2.73 range. That is -8% versus the projected 2030 average. That marks a +34% change versus current levels. Momentum favours further upside here.
By 2032, SBFM could reach as high as $2.71, with a base case around $1.50 and support toward $0.8874 — roughly +29% from $1.17. Buyers look set to stay in control over this stretch.
Expect SBFM to range from $1.05 to $3.41 through 2033. The $1.84 average target implies a +58% move from current prices. That is up +23% on the projected 2032 average. Momentum favours further upside here.
The SBFM price prediction for 2034 points to an average of $2.16 (low $1.18, high $4.09) — a potential gain of +84% on today's $1.17. Buyers look set to stay in control over this stretch.
In 2035, SBFM is projected to trade between $1.21 and $4.41, averaging $2.28 — a potential gain of +95% from today's $1.17. That is up +5% on the projected 2034 average. Momentum favours further upside here.
Sunshine Biopharma, Inc.'s 2040 outlook centres on $2.31, within a $1.04 to $4.89 range. That is up +1% on the projected 2035 average. That marks a +97% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, SBFM could reach as high as $11.07, with a base case around $4.81 and support toward $2.17 — roughly +311% from $1.17. Momentum favours further upside here.
Investing $1,000 in SBFM today (≈ 854.700855 SBFM) could be worth
$4,114.14
+$3,114.14 (+311%) by 2050 · US Dollar
Based on the average projected SBFM price of $4.81 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SBFMwould be worth at today's price.
$1,000 invested in SBFM on Jul 31, 2025 (≈ 694.444417 SBFM) would be worth
$812.5
-$187.5 (-18.8%) today · 0.81× · US Dollar
Based on a SBFM entry price of $1.44 vs. today's $1.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.66 | $704.82 | -29.5% |
| 1 month ago | $2.18 | $536.7 | -46.3% |
| 3 months ago | $1.05 | $1,109 | +10.9% |
| 6 months ago | $1.23 | $951.22 | -4.9% |
| 1 year ago | $1.44 | $812.5 | -18.8% |
| All time (4.5y) ago | $4,780 | $0.24 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SBFM forecast.
Our base-case forecast reaches $2.30 around 2040.
Implied market cap at $2.30: $5.47M
The multi-year forecast shows a bullish path after 2026, with 2027 averaging $1.68 and rising through 2029 to $2.06, then a softer year in 2030 with an average of $1.79 but a continued bullish tilt overall. From 2031 to 2035 the averages trend upward gradually (2031 $1.66; 2032 $1.62; 2033 $1.95; 2034 $2.32; 2035 $2.46), reinforcing a longer-term upside. The 2040 forecast averages $2.48 and the 2050 forecast averages $5.19, with a max of $11.93 and an ROI of 321.7%.
The outlook is described as BULLISH across the later years. These are estimates based on the provided forecast figures and are not guarantees. Market conditions and other factors can cause actual results to differ.
Tap a question to reveal the answer.
2030 avg price is $1.79, with a min of $1.12 and a max of $3.07; ROI is 45.4% and sentiment is BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising averages and a forecast max of $11.93 by 2050 (avg $5.19, ROI 321.7%). These are estimates and not guarantees.
Yes. The 2050 forecast lists a max of $11.93, with an average of $5.19 and ROI of 321.7%.
Current price is $1.23 and market capitalization is $1.99M.
The 30-day range is $0.8732 to $1.73.
Sunshine Biopharma, Inc. Community Discussion
0Share your Sunshine Biopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.